Clinical trial Recruiting at 1 site Interventional

Using an AI tool to prioritize specialty referrals for primary care patients

Official title: Efficacy of an Artificial Intelligence Algorithm for Gatekeeping in Referrals From Primary Care to Specialized Care: a Randomized Controlled Trial

Run by Hospital de Clinicas de Porto Alegre · NCT07019116 · Data updated 2026-11-12

This project will test whether an AI tool can sort and prioritize specialty-care referrals so primary care patients with chronic conditions get more timely and appropriate specialist access.

Quick facts

Study typeInterventional
SexAll
Enrollment934 (estimated)
SponsorHospital de Clinicas de Porto Alegre
Academic / other
Locations1 site (Porto Alegre, Rio Grande do Sul)
StatusRecruiting
StartedNovember 15, 2025
Main results expectedDecember 2028
Study endsDecember 2029
Registry record updatedFebruary 20, 2026
Trial IDNCT07019116 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

This applies to referrals from selected specialty waitlists submitted by primary care clinics across municipalities in Rio Grande do Sul, mainly for patients with chronic conditions.

Probably not a fit

Referrals that include attachments or previous rounds of discussion, or any referral where the AI gives under 80% confidence, are excluded and would not benefit from the tool in this project.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Investigators will randomly implement an AI triage algorithm across selected specialty waitlists in the electronic referral system used in Rio Grande do Sul, Brazil, and compare outcomes to standard gatekeeping. Eligible referrals come from municipal primary care clinics for selected specialties; referrals with attachments, prior discussion rounds, or AI confidence below 80% are excluded. The trial will measure how the AI affects referral authorization patterns, wait times, specialist visit appropriateness, and backlog size. Implementation is centered at the Central de Regulação Ambulatorial in Porto Alegre and coordinated with the state health department.

Why it matters

Potential benefit: If successful, the AI could speed care for high-risk patients, reduce unnecessary specialist visits, and shrink the referral backlog.

How similar studies have gone: Some AI triage tools have shown promise in other referral and emergency-triage settings, but randomized implementation of gatekeeping AI across a large public referral system is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* All referrals from a given specialty (waitlist) will be eligible.
* Specialties will be selected following Rio Grande do Sul Health Department priorities.

Exclusion Criteria:

* Referrals that the AI algorithm can not evaluate. These include referrals with attachments (further information in image or PDF files) and referrals with previous rounds of discussion.
* Referrals in which the algorithm has low confidence in the decision (i.e., informed data lead to a decision with a probability below 80%) will not be included in the study.

Where it's running

  • Central de Regulação Ambulatorial
    Porto Alegre, Rio Grande do Sul, Brazil
    Recruiting

Study contacts

  • Principal investigator: Dimitris V. Rados, Ph.D. — TelessaúdeRS
  • Study coordinator: Dimitris V Rados, Ph.D.
  • Email: drados@hcpa.edu.br
  • Phone: +555133082092

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.